Vicore Pharma Holding AB | Income Statement
Fiscal year is January-December. All values SEK Thousands.
2013
2014
2015
2016
2017
Sales/Revenue
-
-
840.00
852.00
932.00
Cost of Goods Sold (COGS) incl. D&A
40.00
36.00
1,492.00
7,561.00
9,002.00
Gross Income
40.00
36.00
652.00
6,709.00
8,070.00
SG&A Expense
4,423.00
5,786.00
-
-
-
EBIT
4,463.00
5,822.00
4,520.00
6,649.00
8,070.00
Non Operating Income/Expense
2,951.00
858.00
50.00
3.00
4,375.00
Interest Expense
219.00
105.00
-
-
-
Pretax Income
1,720.00
5,018.00
4,570.00
6,652.00
12,445.00
Equity in Affiliates
117.00
18,705.00
-
-
410.00
Consolidated Net Income
1,603.00
13,687.00
4,570.00
6,652.00
12,855.00
Net Income
1,603.00
13,687.00
4,570.00
6,652.00
12,855.00
Net Income After Extraordinaries
1,603.00
13,687.00
4,570.00
6,652.00
12,855.00
Net Income Available to Common
1,603.00
13,687.00
4,570.00
6,652.00
12,855.00
EPS (Basic)
0.20
1.69
0.37
0.54
0.81
Basic Shares Outstanding
8,120.40
8,120.40
12,368.50
12,368.50
15,868.50
EPS (Diluted)
0.20
1.69
0.37
0.54
0.81
Diluted Shares Outstanding
8,120.40
8,120.40
12,368.50
12,368.50
15,868.50
EBITDA
4,423.00
5,786.00
4,514.00
6,643.00
8,063.00
Other Operating Expense
-
-
3,868.00
60.00
-
Non-Operating Interest Income
11.00
51.00
-
-
-
About Vicore Pharma Holding AB
View Profile
